cAIMP administration in humanized mice induces a chimerization-level-dependent STING response.
Anna H F AndersenRikke OlesenKasper L JønssonJesper F HøjenChristian KrappKatharina MackMartin K ThomsenLars ØstergaardMartin TolstrupFrederik Dagnaes-HansenMartin R JakobsenPaul W DentonPublished in: Immunology (2019)
It is well understood that the STING signalling pathway is critical for generating a robust innate immune response to pathogens. Human and mouse STING signalling pathways are not identical, however. For example, mice lack IFI16, which has been proven important for the human STING pathway. Therefore, we investigated whether humanized mice are an appropriate experimental platform for exploring the human STING signalling cascade in vivo. We found that NOG mice reconstituted with human cord blood haematopoietic stem cells (humanized NOG mice) exhibit human STING signalling responses to an analogue of the cyclic di-nucleotide cGAMP. There was an increase in the proportions of monocytes in the lungs of mice receiving cGAMP analogue. The most robust levels of STING expression and STING-induced responses were observed in mice exhibiting the highest levels of human chimerization. Notably, differential levels of STING in lung versus spleen following cGAMP analogue treatment suggest that there are tissue-specific kinetics of STING activation and/or degradation in effector versus inductive sites. We also examined the mouse innate immune response to cGAMP analogue treatment. We detected that mouse cells in the immunodeficient NOG mice responded to the cGAMP analogue and they do so with distinct kinetics from the human response. In conclusion, humanized NOG mice represent a valuable experimental model for examining in vivo human STING responses.
Keyphrases
- endothelial cells
- stem cells
- induced pluripotent stem cells
- high fat diet induced
- pluripotent stem cells
- cord blood
- immune response
- dendritic cells
- escherichia coli
- oxidative stress
- metabolic syndrome
- high glucose
- wild type
- insulin resistance
- pseudomonas aeruginosa
- high throughput
- staphylococcus aureus
- combination therapy
- peripheral blood